, and Veronica Gomez-Lobo, MD 8 I nfertility, or the concern for infertility, has been shown in many studies to be associated with psychosocial distress among affected adults, 1, 2 and may result from numerous genetic or pediatric conditions and treatments. 3 Fertility preservation technologies have been developed to expand future parenthood options for youth and others at risk for infertility. 3 Although these rapid technological advances have facilitated improvements in clinical care, significant knowledge gaps exist with regard to who is at risk and could benefit from fertility preservation technologies, which methods have adequate evidence to support integration in clinical care, and how to optimize access to, and utilization of, established options.
Much of the work in this area has been conducted in pediatric oncology, as chemotherapy and radiation are known to impair gonadal function, and research has informed dosespecific risk assessments for many of the most common treatments. 4, 5 An important limitation of this research is that sexual orientation or gender identity are rarely assessed within study populations, and 1 study has suggested perspectives on parenthood may be different in those within the lesbian, gay, bisexual, transgender, or questioning (LGBTQ) population compared with non-LGBTQ identified cancer survivors. 6 Organizations such as the American Academy of Pediatrics, American Society of Pediatric Oncology, and American Society for Reproductive Medicine have published guidelines urging providers to counsel youth with cancer about their infertility risk; discuss fertility preservation options, distinguishing those that are established (sperm, oocyte, and embryo cryopreservation), from those that are experimental (testicular and ovarian tissue cryopreservation); and to document these discussions and referrals in the medical record. [7] [8] [9] Using this framework, increasing attention has been paid to other populations at risk for infertility, 3, 10, 11 including the rapidly expanding transgender population seeking hormonal therapies. 12 Though little is known about long-term fertility outcomes after these treatments, the American Society for Reproductive Medicine Endocrine Society, and World Professional Association for Transgender Health recently published guidelines highlighting the need to discuss infertility risk and fertility preservation options with youth prior to hormonal interventions. [13] [14] [15] The purpose of the narrative review was to identify what is known about fertility implications related to hormonal treatments in youth (estrogen, testosterone, and gonadotropin-releasing hormone [GnRH] agonists), fertility preservation options in pediatrics, and transgender youths' attitudes toward biological parenthood. This article will report on the results of the narrative review; discuss appropriate fertility preservation options for youth with gender dysphoria; and propose medical and psychological recommendations for best practices related to fertility counseling and intervention, based on the known literature to date.
A literature search was conducted to inform this narrative review, based on applicable PRISMA items. We searched PubMed, Google Scholar, Medline, Web of Science, and PsycInfo databases for English-language studies (no date restrictions on publication year), with the following search terms: transgender, gender identity disorder, gender dysphoria, transsexual, reproductive health, fertility, fertility preservation, ovarian stimulation, prepubertal ovaries, testes, gender-affirming hormones, cross-sex hormones, pubertal suppression, GnRH agonist, testosterone, estrogen, antimullerian hormone (AMH), adolescent, parent, pregnancy, and attitudes. Search results included a variety of publication types including guidelines, commentaries, case series, qualitative, and quantitative research. We also manually searched the references of each selected article. All authors agreed upon which articles to include. Given the dearth of research in this area, inclusion was broad and based on assessment of relevance of content, utility of findings, and appraisal of study methodology and reporting. Human studies were prioritized for inclusion, though relevant animal studies were also included as they related to hormone functioning and fertility.
Effects of Hormone Therapy on Fertility

Effects of Estrogen Therapy on the Testicle
Few studies specific to the transgender community exist to guide conversations about the long-term effects of gender-affirming hormones on testicular function and fertility. Studies of the effects of estrogen secreting tumors in male subjects have documented spermatogenesis after tumor removal even after prolonged (months to years) abnormal hormonal function. 16, 17 
AMH
Antimullerian hormone GnRH Gonadotropin-releasing hormone Studies examining the use of high dose estrogen for the treatment of prostate disease have been reported to cause azoospermia and atrophy due to gonadotropin suppression and Leydig cell dysfunction with variable reversibility. 18, 19 Animal data suggest that the role of physiologic estrogen in testicular function and fertility is more complex. 20 The few available studies of transgender women on estrogen therapy rely on small sample sizes (n = 1 to n = 11) and heterogeneous treatment protocols (low or high dose estrogen, estrogen + anti-androgens, oral vs transdermal) resulting in incomplete and often conflicting results. 21 Prolonged estrogen exposure has been reported to result in atrophy and absent or impaired spermatogenesis, 22, 23 while normal spermatogenic activity and complete reversibility have also been reported. [24] [25] [26] One recent study reported heterogeneous results among 108 transgender women presenting for gender-affirming surgery after gender-affirming hormone treatment ranging from normal spermatogenesis (24%) to tubular shadows/atrophy (1.85%).
27
Effects of Testosterone Therapy on the Ovary Despite the fact there have been a few pregnancies in transgender men widely publicized in the popular press, the overall pregnancy rate has not been published, 28 and the effect of long-term gender-affirming hormone therapy on fertility in transgender men is considered unknown. There is 1 published study on pregnancy in transgender men, of whom 61% of participants were on testosterone prior to pregnancy. 29 Of these subjects, 84% used their own oocytes for pregnancy, and 32% conceived while still on testosterone. 29 Importantly, this study only included subjects who had a live birth, so does not capture overall conception or miscarriage rates in this population. 29 Most of the data on the effects of testosterone therapy on the ovaries of transgender men have come from case series examining the ovaries at the time of gender-affirming surgery with salpingo-oophorectomy, with conflicting results. [30] [31] [32] [33] [34] [35] [36] [37] Four of these studies reported a definitive adverse effect on the histology of the ovary, reporting a polycystic ovarian morphology (stromal hyperplasia, multiple cystic follicles, collagenized outer cortex, and/or luteinization of stromal cells) in the majority of ovaries examined. 30, 32, 33, 36 Three of the studies concluded that there is minimal to no adverse effect on the ovaries, 31, 34, 35 and the remaining study was somewhere in between. 37 Of note, all of these studies were performed in adults, and the average duration of testosterone therapy was less than 4 years in all 8 studies, so it is unclear whether these data can be applied to an individual who initiated gender-affirming hormones in adolescence, and then desires fertility more than a decade later. There are also 2 studies that evaluated AMH levels in transgender men after gender-affirming hormone therapy; 1 study showed a decrease in AMH, and the other showed no change, and both studies had the patients on additional hormone-affecting medications (GnRH agonist, aromatase inhibitor, and/or progestin) making it difficult to isolate the specific effect of testosterone, and any potential effect on ovarian reserve.
38,39
Gonadal Effects in Adolescents who have Undergone Puberty Suppression
There is a paucity of literature on the effects of pubertal suppression by GnRH agonists in transgender youth on future reproduction, although studies of GnRH agonists used for male contraception have demonstrated reversible suppression of spermatogenesis. 40 Schagen et al reported a decrease in testicular volume among the majority of 49 transgender youth receiving GnRH agonists. 41 Similarly, a study on the effect of GnRH agonist treatment in girls with central precocious puberty showed a decrease in ovarian and uterine size during treatment, with increase to normal size and resumption of menstrual function approximately 1 year after cessation of therapy. 42 Currently, no studies address whether fertility can be gained, either naturally or with exogenous gonadotropins, in transgender individuals who underwent pubertal suppression in adolescence, followed directly by gender-affirming hormone therapy. Fertility can be gained in those who undergo pubertal suppression and then discontinue GnRH agonists to allow endogenous puberty to progress, though there may be negative psychosocial implications of this process for some youth who may progress through puberty incongruent with their affirmed gender identity.
Overview of Current Fertility Preservation Options
A wide range of fertility preservation methods are considered in children, adolescents, and young adults with cancer, and in part inform options for transgender individuals depending on sex assigned at birth and pubertal development ( Table I and Table II) . 43 For pubertal (Tanner stages 2-3 and beyond) assigned male subjects, sperm cryopreservation is a safe, established, and cost-effective fertility preservation method. 44 Noninvasive methods (masturbation) are preferred, though sperm may be retrieved by electroejaculation 45 or extracted with percutaneous aspiration or microdissection extraction of the testicular sperm for those who are unwilling or unable to masturbate, or who are azoospermic. 46, 47 These alternate methods could benefit individuals whose erections have decreased after starting gender-affirming therapy, or for those who experience psychological distress with masturbation. At present, testicular tissue cryopreservation for preand postpubertal assigned male subjects is an experimental fertility preservation option 48, 49 ; because no human births have been reported to date, this procedure should only be performed under an institutional review board-approved protocol for those who are at high risk for infertility. 50 Among assigned female subjects who have experienced menarche, embryo cryopreservation is an established fertility preservation method, and requires sperm from a partner or donor and postpubertal egg from the patient. In 2013, oocyte cryopreservation became an established method of fertility preservation in this population with improved cryopreservation techniques, 51 and successful pregnancies have been reported. 52 However, it remains unclear whether ovaries can be effectively stimulated in youth who have started GnRH agonists in and has resulted in more than 100 successful live births. 54, 55 Notably, nearly all of these births have resulted from postpubertal ovarian tissue 56 ; live births have only been reported with reimplantation of the tissue back into the donor 57 ; and because removal of 1 complete ovary is often required in pediatric patients, this procedure is only offered to those at moderatehigh risk for infertility. 53 
Attitudes toward Fertility Preservation
Transgender adults have wide-ranging attitudes toward and experiences of fertility preservation and parenthood; prior research shows 18%-54% of transgender adults express desires for children. [58] [59] [60] [61] Parenting desires are associated with younger age and support from family, 61 and currently not having a child. 59, 60 The experience of parenting children after medical transition has been described by some as a meaningful part of life, connecting individuals to the larger community. 62 Two recent case series document transgender adults using assisted reproductive technologies and cryopreserved gametes to would require progression through early endogenous puberty (which could lead to potentially distressing irreversible changes to the voice, hair, facial/ body structure) so an adequate sperm sample can be obtained through the methods described above.
Estimated costs* Preservation
• $400-$1000 for collection • $200-$500/y for storage • $45-$100 for thawing Thawing and fertilization
• Additional costs may be incurred with use of sperm, which will require either intrauterine inseminations or in vitro fertilization, depending on sample quality.
Testicular tissue cryopreservation (prepubertal)
• Based on current knowledge, we recommend against offering testicular tissue cryopreservation to minors. o Although estrogen may cause irreversible damage to sperm production, to date, there has never been a human pregnancy reported through testicular tissue cryopreservation.
• Testicular cryopreservation may be performed at the time of gonadectomy, but patients should be counseled regarding the experimental nature, lack of documented pregnancy, and costs of storage of testicular tissue.
Estimated costs* Preservation
• $5000-$10 000 for surgery (may be free at some centers if done through a research protocol) • $150 for transportation to storage site • $100-$1000/y for storage Tissue thawing and use
• Costs are unknown as it is unclear if pregnancy will be achieved through in vitro sperm maturation or testicular tissue transplant.
*Costs may vary widely between centers across the US and internationally.
Table II. Fertility preservation methods for assigned female patients
Oocyte and embryo cryopreservation (Pubertal only)
• Late-and postpubertal individuals may undergo stimulation and oocyte retrieval for oocyte or embryo cryopreservation. o Individuals who have undergone pubertal suppression prior to beginning testosterone therapy may require progression through early endogenous puberty (which could lead to potentially distressing irreversible chest tissue growth and hip widening) prior to ovarian stimulation and oocyte retrieval and cryopreservation.
Estimated costs* Preservation • $5000-$20 000 for monitoring, oocyte retrieval, and lab procedures • $4000-$5000 for medications • $100-$1000/y for storage Thawing, fertilization, and implantation • $3000-$10 000 for lab and medical procedures • $100-$1000 for medications Ovarian tissue cryopreservation (Pre-pubertal or pubertal) • Although ovarian tissue cryopreservation remains experimental, to date there have been over 100 pregnancies reported in individuals who have had tissue re-implanted.
• Given the documented pregnancies in transgender men even while on testosterone therapy, and the fact that ovarian tissue cryopreservation is generally reserved for those at moderate-high risk of infertility, we believe that the risks of ovarian tissue cryopreservation outweigh the benefits, and it should not be offered to adolescents prior to initiating testosterone therapy. COMMENTARY build biological families. 63, 64 It is important to note that qualitative work with adult transgender men demonstrates varying psychosocial experiences with fertility preservation. Some transgender men who temporarily discontinued testosterone to pursue fertility preservation experienced worsening gender dysphoria with resumption of menses, whereas others felt the experience was less distressing than anticipated. 65 In previously studied samples of transgender adults, 38% of transgender men 59 and 51% of transgender women 60 indicated they would have considered gamete (ie, sperm or egg) cryopreservation if this technology had existed and been offered to them. Among transgender women, identifying as lesbian or bisexual and younger age are associated with greater likelihood of considering sperm cryopreservation. 60 Many transgender men and women also agree that fertility preservation should be offered prior to gender-affirming medical treatment. 60, 62 Regardless of individual desires, provider and systemic barriers such as cost ( Table I and Table II) , and discrimination/refusal of services, may impede transgender individuals' ability to pursue reproductive services.
Few studies have specifically examined fertility desires and parenting intentions among a growing population of transgender youth seeking gender-affirming hormonal therapies in adolescence. To date, 2 studies have reported low fertility preservation utilization rates in this population, with 1 institution identifying that out of 72 transgender youth counseled on fertility, only 2 (3%) pursued fertility preservation (both assigned male subjects). 66 Another pediatric institution reported 5 patients (4 assigned male patients) out of 105 (5%) pursued fertility preservation. 67 In a pilot study of 25 transgender youth surveyed about their fertility-related attitudes, only 24% expressed a desire to have their own biological child and none had pursued fertility preservation; however, many wondered if their attitudes toward biological parenthood may change in the future. 68 Similarly, in a recent mixed-methods study of a more genderdiverse sample of 156 community-recruited transgender and gender-nonconforming 14-to 17-year-olds (in which just over one-half identified as genderqueer), 36% expressed interest in biological parenthood; however, an additional 26% expressed uncertainty about biological parenthood desires. Notably, 60% of this sample were interested in learning more about their fertility options, which was consistent with qualitative reports pointing to the need for additional information about "fertility for people who are transitioning from one gender to another." 69 A validated questionnaire was recently developed to explore fertility-related attitudes among transgender adolescents and may be useful for future work in this area; efforts should be made in this future research to examine fertilityrelated perspectives of nonbinary or gender fluid adolescents as well. 68 It is also important to note that fertility desires are not the only consideration in making decisions about pursuing fertility preservation; risks of worsening gender dysphoria to pursue gamete cryopreservation is an important individual factor, as documented in a recent case report of 2 transmasculine adolescents who ultimately made different decisions about fertility preservation. 70 There is also limited research on the perspectives of parents of transgender youth regarding their children's future fertility. One European study ranking priorities among parents of transgender youth ranked "future children" as their lowest priority, particularly among parents of children assigned male. 71 Strang et al in a study of transgender youth fertility attitudes identified that 65% of parents felt it was important to learn the impact of gender-affirming hormone treatment on their child's ability to have children in the future. 68 Of these, 56% o Medical providers should discuss the medical implications of interventions on fertility, options available for fertility preservation, and alternative options for family building. o When available, mental health staff should meet with youth and families to better understand the unique concerns of the child/adolescent and caregivers, including cultural, structural, mental health and other considerations, and ensure youth and families have an adequate understanding of topics discussed with medical providers.
• Allow adequate time for discussion and decision-making. Counseling and informed consent should ideally be a multi-session process, allowing time for contemplation, with the recognition that attitudes toward fertility preservation can modify with time and youth/caregiver reflection. However, this timeline must be balanced to account for potential distress that may occur with waiting to initiate treatment, to determine an individualized plan for each youth/family, including the potential option to temporarily discontinue hormonal intervention in the future to pursue fertility preservation and the risks/benefits of this.
• Use a flexible approach within the structured protocol that can be modified based on possible developmental and mental health challenges of the youth and parents. o A different approach may be necessary in cases in which family conflict is high, and/or if a child/adolescent is experiencing significant mental health morbidities in the absence of intervention. o Developmental diagnoses, such as autism spectrum disorders, can co-occur with gender dysphoria, and approaches to counseling should be modified to ensure adequate communication, sometimes in consultation with other providers with the necessary expertise (eg, autism spectrum disorder specialists). wanted their child to consider fertility preservation methods. 68 Conversely, Lawlis et al asked 118 transgender and gendernonconforming youth and their parents (n = 103) to endorse items of health concern among a list of 22 concerns. Concerns about fertility were endorsed by only 8 (7%) youth and 10 (10%) of parents. 72 The majority of parents were more focused on issues such as their child's mental health concerns and how to keep their child safe at school. 72 
Conclusions
Transgender youth may be interested in becoming biological parents, and should be counseled about potential risk of fertility impairment and fertility preservation options before initiation of hormonal or surgical therapies which may impact reproductive potential. Based on the current state of knowledge (with limited information about the impact of hormonal therapies on fertility), we suggest fertility preservation methods be limited to those deemed "standard of care" for pubertal youth not on hormone therapy (Table I and Table II) . Similar to onco fertility standards of care, the approach to fertility counseling should use the diverse skill sets represented on interdisciplinary teams, with a structured protocol to ensure that issues of fertility and alternative family building options are adequately discussed with each child and family (Table III) .
Prior studies indicate it is relatively rare for transgender youth to opt for fertility preservation interventions. 66, 67 Although reasons for this reluctance are not entirely clear, a number of barriers exist, 11, 69 including developmental (age), cognitive (focus on establishing gender identity), structural (cost, invasiveness), and provider (knowledge, resources) challenges. Ethical concerns centering on the principles of autonomy (parent/ child decisional conflict about hormonal therapies and fertility preservation) and justice (inability to access fertility preservation treatments because of due to cost) are common. 73 Further research is needed to develop evidence-based strategies to overcome these barriers, examine effects of genderaffirming hormones on gametes, 74 and identify optimal strategies to obtain gametes without requiring pubertal changes that do not align with the individual's gender identity in individuals who undergo puberty suppression. ■ Submitted for publication Apr 23, 2018 ; last revision received Aug 14, 2018; accepted Sep 5, 2018 Reprint requests: Leena Nahata, MD, Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH 43205. E-mail: leena.nahata@ nationwidechildrens.org
